

BIOCRYST PHARMACEUTICALS INC

Form 8-K

May 22, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2015

BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-23186 62-1413174

*(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation)*

File Number) Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices)

(919) 859-1302

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc. (the “Company”), was held on May 20, 2015 for the purpose of: (i) electing one director to serve for a term of three years and until a successor is duly elected and qualified; and (ii) ratifying the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2015.

The nominee for director was elected by the following votes:

	<u>FOR</u>	<u>WITHHELD</u>
Nancy Hutson	<u>47,388,865</u>	<u>408,460</u>

In addition, there were 17,845,504 broker non-votes.

The proposed ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2015 was approved by the following votes:

FOR	<u>64,482,680</u>
AGAINST	<u>1,040,763</u>
ABSTAIN	<u>119,386</u>

There was no other business voted upon at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 22, 2015 **BioCryst Pharmaceuticals, Inc.**

By: /s/ Alane Barnes
Alane Barnes
Vice President, General Counsel,
and Corporate Secretary